Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where A.L. Beavis is active.

Publication


Featured researches published by A.L. Beavis.


Cancer | 2017

Hysterectomy-corrected cervical cancer mortality rates reveal a larger racial disparity in the United States.

A.L. Beavis; Patti E. Gravitt; Anne F. Rositch

The objectives of this study were to determine the age‐standardized and age‐specific annual US cervical cancer mortality rates after correction for the prevalence of hysterectomy and to evaluate disparities by age and race.


Frontiers in Oncology | 2016

Preventing Cervical Cancer in the United States: Barriers and Resolutions for HPV Vaccination.

A.L. Beavis; Kimberly L. Levinson

Human papillomavirus (HPV) vaccination rates for preadolescent and adolescent girls in the United States are far behind those of other developed nations. These rates differ substantially by region and state, socioeconomic status, and insurance status. In parents and young women, a lack of awareness and a misperception of the risk of this vaccine drive low vaccination rates. In physicians, lack of comfort with discussion of sexuality and the perception that the vaccine should be delayed to a later age contribute to low vaccination rates. Patient- and physician-targeted educational campaigns, systems-based interventions, and school-based vaccine clinics offer a variety of ways to address the barriers to HPV vaccination. A diverse and culturally appropriate approach to promoting vaccine uptake has the potential to significantly improve vaccination rates in order to reach the Healthy People 2020 goal of over 80% vaccination in adolescent girls. This article reviews the disparities in HPV vaccination rates in girls in the United States, the influences of patients’, physicians’, and parents’ attitudes on vaccine uptake, and the proposed interventions that may help the United States reach its goal for vaccine coverage.


Gynecologic Oncology | 2016

Sentinel lymph node detection rates using indocyanine green in women with early-stage cervical cancer

A.L. Beavis; Sergio Salazar-Marioni; A.K. Sinno; Rebecca L. Stone; Amanda Nickles Fader; Antonio Santillan-Gomez; Edward J. Tanner

OBJECTIVE Our study objective was to determine feasibility and mapping rates using indocyanine green (ICG) for sentinel lymph node (SLN) mapping in early-stage cervical cancer. METHODS We performed a retrospective review of all women who underwent SLN mapping with ICG during primary surgical management of early-stage cervical cancer by robotic-assisted radical hysterectomy (RA-RH) or fertility-sparing surgery. Patients were treated at two high-volume centers from 10/2012 to 02/2016. Completion pelvic lymphadenectomy was performed after SLN biopsy; additionally, removal of clinically enlarged/suspicious nodes was part of the SLN treatment algorithm. RESULTS Thirty women with a median age of 42.5 and BMI of 26.5 were included. Most (90%) had stage IB disease, and 67% had squamous histology. RA-RH was performed in 86.7% of cases. One patient underwent fertility-sparing surgery. Median cervical tumor size was 2.0cm. At least one SLN was detected in all cases (100%), with bilateral mapping achieved in 87%. SLN detection was not impacted by tumor size and was most commonly identified in the hypogastric (40.3%), obturator (26.0%), and external iliac (20.8%) regions. Five cases of lymphatic metastasis were identified (16.7%): three in clinically enlarged SLNs, one in a clinically enlarged non-SLN, and one case with cytokeratin positive cells in an SLN. All metastatic disease would have been detected even if full lymphadenectomy had been omitted from our treatment algorithm, CONCLUSIONS: SLN mapping with ICG is feasible and results in high detection rates in women with early-stage cervical cancer. Prospective studies are needed to determine if SLN mapping can replace lymphadenectomy in this setting.


International Journal of Women's Health | 2016

Lifestyle changes and the risk of developing endometrial and ovarian cancers: opportunities for prevention and management

A.L. Beavis; Anna Jo Bodurtha Smith; Amanda Nickles Fader

Modifiable lifestyle factors, such as obesity, lack of physical activity, and smoking, contribute greatly to cancer and chronic disease morbidity and mortality worldwide. This review appraises recent evidence on modifiable lifestyle factors in the prevention of endometrial cancer (EC) and ovarian cancer (OC) as well as new evidence for lifestyle management of EC and OC survivors. For EC, obesity continues to be the strongest risk factor, while new evidence suggests that physical activity, oral contraceptive pills, and bariatric surgery may be protective against EC. Other medications, such as metformin and nonsteroidal anti-inflammatory drugs, may be protective, and interventional research is ongoing. For OC, we find increasing evidence to support the hypothesis that obesity and hormone replacement therapy increase the risk of developing OC. Oral contraceptive pills are protective against OC but are underutilized. Dietary factors such as the Mediterranean diet and alcohol consumption do not seem to affect the risk of either OC or EC. For EC and OC survivors, physical activity and weight loss are associated with improved quality of life. Small interventional trials show promise in increasing physical activity and weight maintenance for EC and OC survivors, although the impact on long-term health, including cancer recurrence and overall mortality, is unknown. Women’s health providers should integrate counseling about these modifiable lifestyle factors into both the discussion of prevention for all women and the management of survivors of gynecologic cancers.


Gynecologic Oncology | 2018

A contemporary framework of health equity applied to gynecologic cancer care: A Society of Gynecologic Oncology evidenced-based review

Sarah M. Temkin; B.J. Rimel; Amanda S. Bruegl; Camille C. Gunderson; A.L. Beavis; Kemi M. Doll

Health disparities are defined as the preventable difference in the burden of disease, injury, and violence, or opportunity to achieve optimal health that socially disadvantaged populations experience compared to the population as a whole. Disparities in incidence and cancer outcomes for women with gynecologic malignancies have been well described particularly for American women of Black race. The etiology of these disparities has been tied to socio-economics, cultural, educational and genetic factors. While access to high quality treatment has been primarily linked to survival from cervical and ovarian cancer, innate biologic distinctions have been principally cited as reasons for differences in incidence and mortality in cancers of the uterine corpus. This article will update the framework of disparities to incorporate a broader understanding of the social determinants of health and how they affect health equity by addressing the root causes of disparities within the health care system. Special populations are identified who are at risk for health inequities which include but are not limited to Black race, underserved racial and ethnic minorities (e.g. indigenous peoples, low English fluency), trans/gender nonconforming people and rural populations. Each of these populations at risk have unique structural barriers within the healthcare system impacting gynecologic cancer outcomes. The authors provide practical recommendations for practitioners aimed at eliminating cancer related outcome disparities.


Current Obstetrics and Gynecology Reports | 2017

HPV Vaccination: Are We Meeting Our Targets in Cervical Cancer Prevention?

A.L. Beavis; Anne F. Rositch; Melinda Krakow; Kimberly L. Levinson

Purpose of ReviewThe purpose of this review is to update the reader on the most recent HPV vaccine uptake rates in boys and girls in the United States and to summarize the recent recommendations for vaccination. The review also evaluates a decade of data demonstrating the safety and efficacy of the HPV vaccine and discusses disparities in vaccine uptake in the US. Finally, we will summarize the scope of attempted and proposed interventions to improve vaccine uptake in the United States.Recent FindingsTopics discussed in this review include the recommendations for the nine-valent HPV vaccine and the two-dose injection regimen. Additionally, many studies reviewed demonstrate continued disparities in HPV vaccine uptake in the US. An update on various interventions to address poor uptake is provided.SummaryDespite being FDA-approved since 2006, only 42% of US adolescent girls and 28% of boys had completed the HPV vaccine series in 2015, well below the Healthy People 2020 goal of 80%. A decade of data has proven that the vaccine is safe and effective. Physician recommendation is consistently the strongest predictor of vaccine uptake, and initiation and recommendation rates differ by region, race, sexual orientation, and socioeconomic status. Special populations, including sexual minorities and children with chronic medical conditions, have particularly low rates of vaccination, representing addressable missed opportunities for vaccination. Interventions to improve uptake have ranged from education to state mandates, with variable effectiveness. Culturally sensitive, multimodal, tailored interventions to improve uptake may hold the most promise, including the use of novel delivery locations such as pharmacies, schools, and the postpartum visit. This article reviews a decade of data on vaccine safety, efficacy, disparities, and interventions to improve vaccination rates, focusing on the most recent year of published data.


Journal of Adolescent Health | 2017

Characteristics of Adolescents Lacking Provider-Recommended Human Papillomavirus Vaccination

Melinda Krakow; A.L. Beavis; Olivia Cosides; Anne F. Rositch


Gynecologic Oncology | 2017

Reasons for persistent suboptimal rates of HPV vaccination in the US: Shifting the focus from sexuality to education and awareness

A.L. Beavis; M. Krakow; Kimberly L. Levinson; Anne F. Rositch


Journal of Adolescent Health | 2018

Reasons for Lack of HPV Vaccine Initiation in NIS-Teen Over Time: Shifting the Focus From Gender and Sexuality to Necessity and Safety

A.L. Beavis; Melinda Krakow; Kimberly L. Levinson; Anne F. Rositch


Gynecologic Oncology | 2018

Gender differences in reasons for lack of HPV vaccination in 2015: Tailoring the cancer-prevention vaccine message

A.L. Beavis; M. Krakow; Kimberly L. Levinson; Anne F. Rositch

Collaboration


Dive into the A.L. Beavis's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

A.K. Sinno

Johns Hopkins University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

B.J. Rimel

Cedars-Sinai Medical Center

View shared research outputs
Top Co-Authors

Avatar

Patti E. Gravitt

George Washington University

View shared research outputs
Researchain Logo
Decentralizing Knowledge